RT Journal Article
SR Electronic
T1 Late-breaking abstract: MAGNETIC; a randomised, double blind, placebo controlled study of nebulised magnesium sulphate in acute asthma in children
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1406
VO 38
IS Suppl 55
A1 Colin Powell
YR 2011
UL http://erj.ersjournals.com/content/38/Suppl_55/1406.abstract
AB MAGNETIC is a double blind randomised placebo controlled study in acute asthma. Children between 2 and 16 years with acute severe asthma were randomized to receive standard care of three doses of nebulised salbutamol and ipratropium bromide every 20 minutes in the first hour with either placebo or nebulised magnesium (250 mmol/L, 151 mg/dose). Primary outcome was asthma severity score (ASS; 0-9) at 60 minutes post treatment; secondary outcomes were length of stay (LOS), need for intravenous (IV) bronchodilator treatment, need for PICU/intubation, stepping down of treatment at one hour, number of additional salbutamol administrations and serious adverse events.506 children (median age 4.0 years; 58% male) were recruited from 30 centres. 251 children received treatment A and 255 children, treatment B. There were no clinical differences in baseline characteristics and no severe serious adverse events in either group.View this table:Primary and secondary outcomesThere was no clinically significant difference in asthma severity score at 60 minutes post treatment. Treatment B significantly reduces the likelihood of intubation and need for intensive care admission.